Product Information
BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB is a generic product labeled by Quagen Pharmaceuticals LLC, priced at $0.5709 per EA under NDC 70752014810. Its NADAC has been published 99 times since Nov 13, 2024.
FDA first approved this application on Jan 18, 2024. Its Orange Book therapeutic-equivalence code is AA.
Strength
325; 50 mg/1; mg/1
Manufacturer
Quagen Pharmaceuticals LLCNDC
70752014810
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACETAMINOPHEN; BUTALBITALApproval Type
Generic (ANDA)
FDA Application
ANDA214291FDA Approved
1/18/2024
TE Code
AA
On Market Since
5/1/2024
Pharmacological Classes
Price Statistics
The NADAC for BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB has been published 99 times since Nov 13, 2024, and over the history we have for it it has declined 14.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5709 per EA |
|---|---|
| All-time high | $0.7122 (Mar 11, 2026) |
| All-time low | $0.4121 (Nov 20, 2024) |
| 52-week high | $0.7122 |
| 52-week low | $0.5411 |
| Median price | $0.6187 |
| Average price | $0.6072 |
| Largest weekly change | -38.3% (Nov 20, 2024) |
| Weeks tracked | 99 |
| Tracking since | Nov 13, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the BUTALBITAL and ACETAMINOPHEN market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Quagen Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
BUTALBITAL and ACETAMINOPHEN market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Barbiturate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB, manufactured by Quagen Pharmaceuticals LLC, is $0.5709 per EA (NDC 70752014810), effective Sep 30, 2026.
How has the price of BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB changed over time?
Over the history we have for it, the NADAC for BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB has declined 14.5%. It has been tracked across 99 weekly CMS publications since Nov 13, 2024.
What are the highest and lowest recorded NADAC prices for BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB?
Since Nov 13, 2024, the NADAC for BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB has ranged from a low of $0.4121 (Nov 20, 2024) to a high of $0.7122 (Mar 11, 2026), with a median of $0.6187 per EA.
Are there cheaper alternatives to BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB?
BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB (NDC 70752014810) is labeled by Quagen Pharmaceuticals LLC, and CMS classifies it as a generic product.